Literature DB >> 18178062

Self-reported motivation to smoke in schizophrenia is related to antipsychotic drug treatment.

Alasdair M Barr1, Ric M Procyshyn, Philip Hui, Joy L Johnson, William G Honer.   

Abstract

PURPOSE: The prevalence of smoking in schizophrenia has reliably been reported as being higher than for any other psychiatric disorder. While a number of theories have been proposed to account for such high rates of smoking, little is known about the subjective motivation for why schizophrenia patients smoke in comparison with those without the disease.
OBJECTIVES: The aim of the present study was to evaluate and compare smoking motivation in control subjects and schizophrenia patients, and determine if factors such as type of medication or access to cigarettes could contribute to self-reported motivation for smoking.
METHODS: We assessed motivation to smoke in 61 schizophrenia inpatients and 33 non-psychiatric health worker controls at a tertiary care psychiatric facility in a cross-sectional study. Nicotine dependency and smoking behavior were evaluated using the Fagerstrom Test for Nicotine Dependence and a validated questionnaire that assesses motivation for smoking along seven different dimensions.
RESULTS: Schizophrenia patients reported a stronger motivation to smoke than controls for reasons related to pleasure from the act of smoking, as well as a need for psychomotor stimulation. Scores on both these factors were significantly associated with daily antipsychotic drug dose. The sedative and anxiolytic effects of smoking were related to anticholinergic load of psychiatric medications.
CONCLUSION: The findings highlight important differences in self-reported motivation to smoke between schizophrenia patients and normals. Antipsychotic drugs may also influence aspects of motivation to smoke.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18178062     DOI: 10.1016/j.schres.2007.11.027

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  22 in total

Review 1.  Schizophrenia and tobacco smoking comorbidity: nAChR agonists in the treatment of schizophrenia-associated cognitive deficits.

Authors:  Manoranjan S D'Souza; Athina Markou
Journal:  Neuropharmacology       Date:  2011-02-01       Impact factor: 5.250

2.  Perception of smoking risks and motivation to quit among nontreatment-seeking smokers with and without schizophrenia.

Authors:  Deanna L Kelly; Heather G Raley; Suzanne Lo; Katherine Wright; Fang Liu; Robert P McMahon; Eric T Moolchan; Stephanie Feldman; Charles M Richardson; Heidi J Wehring; Stephen J Heishman
Journal:  Schizophr Bull       Date:  2010-11-01       Impact factor: 9.306

Review 3.  The co-occurrence of cigarette smoking and bipolar disorder: phenomenology and treatment considerations.

Authors:  Jaimee L Heffner; Jeffrey R Strawn; Melissa P DelBello; Stephen M Strakowski; Robert M Anthenelli
Journal:  Bipolar Disord       Date:  2011 Aug-Sep       Impact factor: 6.744

Review 4.  Smoking in schizophrenic patients: A critique of the self-medication hypothesis.

Authors:  Francesca Manzella; Susan E Maloney; George T Taylor
Journal:  World J Psychiatry       Date:  2015-03-22

Review 5.  Targeting neuronal dysfunction in schizophrenia with nicotine: Evidence from neurophysiology to neuroimaging.

Authors:  Jason Smucny; Jason R Tregellas
Journal:  J Psychopharmacol       Date:  2017-04-26       Impact factor: 4.153

Review 6.  The role of antipsychotics in smoking and smoking cessation.

Authors:  Annette M Matthews; Vanessa B Wilson; Suzanne H Mitchell
Journal:  CNS Drugs       Date:  2011-04       Impact factor: 5.749

7.  Development of a cost-efficient novel method for rapid, concurrent genotyping of five common single nucleotide polymorphisms of the brain derived neurotrophic factor (BDNF) gene by tetra-primer amplification refractory mutation system.

Authors:  Cathy K Wang; Michael S Xu; Colin J Ross; Ryan Lo; Ric M Procyshyn; Fidel Vila-Rodriguez; Randall F White; William G Honer; Alasdair M Barr
Journal:  Int J Methods Psychiatr Res       Date:  2015-06-29       Impact factor: 4.035

8.  Nicotine dependence is associated with depression and childhood trauma in smokers with schizophrenia: results from the FACE-SZ dataset.

Authors:  Romain Rey; Thierry D'Amato; Laurent Boyer; Lore Brunel; Bruno Aouizerate; Fabrice Berna; Delphine Capdevielle; Isabelle Chereau; Gabrielle Chesnoy-Servanin; Hélène Denizot; Jean-Michel Dorey; Caroline Dubertret; Julien Dubreucq; Catherine Faget; Franck Gabayet; Christophe Lancon; Jasmina Mallet; David Misdrahi; Christine Passerieux; Aurélie Schandrin; Franck Schürhoff; Mathieu Urbach; Pierre Vidailhet; Pierre-Michel Llorca; Guillaume Fond
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-04-07       Impact factor: 5.270

9.  Smoking expectancies and intention to quit in smokers with schizophrenia, schizoaffective disorder and non-psychiatric controls.

Authors:  Jennifer W Tidey; Damaris J Rohsenow
Journal:  Schizophr Res       Date:  2009-12       Impact factor: 4.939

10.  Smoking topography and outcome expectancies among individuals with schizotypy.

Authors:  Diana W Stewart; Christine Vinci; Claire E Adams; Alex S Cohen; Amy L Copeland
Journal:  Psychiatry Res       Date:  2012-12-20       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.